Table 4.
Serum Anti-Als3 Total Immunoglobulin G Antibody Titers (0–360 Days) for the Per Protocol Population
| Treatment Group | GeoMean Dilution-1 (GeoSD) | |||||
|---|---|---|---|---|---|---|
| Day 0 | Day 14 | Day 28 | Day 90 | Day 180 | Day 360 | |
| Total anti-Als3 IgG | ||||||
| Placebo | 465 (3.3) | 464 (3.6) | 419 (3.3) | 447 (3.2) | 523 (3.5) | 371 (3.6) |
| NDV-3A | 434 (3.5) | 37,381 (3.9)* | 31,459 (3.6)* | 17,818 (3.5)* | 10,852 (3.5)* | 5349 (3.2)* |
| NDV-3 | 305 (3.8) | 18,078 (4.6)* | 13,674 (4.6)* | 10,868 (3.8)* | 6,297 (3.9)* | 4999 (3.9)* |
| Total anti-Als3 IgA1 | ||||||
| Placebo | 937 (5.6) | 954 (6.4) | 850 (5.5) | 1062 (6.0) | 982 (7.3)* | 563 (7.3) |
| NDV-3A | 1011 (5.5) | 63,834 (5.1)* | 43,557 (5.2)* | 23,053 (5.1)* | 18,215 (5.9)* | 8727 (5.8)* |
| NDV-3 | 657 (3.1) | 44,866 (3.7)* | 30,118 (3.2)* | 20,349 (3.1)* | 14,633 (3.4)* | 12,357 (3.1)* |
P values to compare the log-transformed values of NDV-3A with NDV-3 were all >.10. *P < .001 for differences in the log-transformed values for vaccine versus placebo.
Abbreviations: IgA1, immunoglobulin A1; IgG, immunoglobulin G.